Cai, Rui
Decuypere, Flore
Chevalier, Pierre
Desseilles, Martin
Lambert, Martin
Fakra, Eric
Wimmer, Antonie
Guillon, Pascal
Pype, Stefan
Godet, Annabelle
Borgmeier, Valeria
Article History
Received: 4 October 2021
Accepted: 28 February 2022
First Online: 7 June 2022
Declarations
:
: Ethical approval was not required for this research article as only deidentified/anonymized electronic databases were used. It was therefore not necessary to acquire any administrative permissions and/or licenses to access clinical/personal data used in this research.The exception to the ethical approval can be found in Article 3, ยง2 of the Experiments Act of 7 May 2004. This article describes the scope of this law and explicitly excludes retrospective studies:BlockQuote removedSince retrospective studies do not fall within the scope of this law, there was consequently no need to obtain ethical approval.The database used in the study comply with the Health Insurance Portability and Accountability Act (HIPAA) regulations.
: Not applicable.
: Rui Cai and Pierre Chevalier are employees at IQVIA, and when drafting the manuscript Flore Decuypere was an employee at IQVIA, which was sponsored by Janssen in the context of this study.Annabelle Godet, Antonie Wimmer, Stefan Pype and Valeria Borgmeier are employees of Janssen, and when drafting the manuscript Pascal Guillon was an employee of Janssen, the sponsor of this study.Martin Desseilles has no competing interests. Martin Lambert: receives consultant or speaker fees from AstraZeneca, Bristol-Myers Squibb, Lilly Deutschland GmbH, Janssen Cilag GmbH, Lundbeck GmbH, Otsuka Pharma GmbH, Roche Deutschland Holding GmbH, Sanovi Aventis, Trommsdorff GmbH & Co KG. Eric Fakra has consulted for Bristol Myers Squibb, Janssen-Cilag, Lilly, Lundbeck, Otsuka, Recordatti, Sanofi; and has lectured for Abbvie, AstraZeneca, Bristol Myers Squibb, Janssen- Cilag, Lundbeck, Otsuka, MSD, Sanofi